News Image

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

Provided By Globe Newswire

Last update: Jun 22, 2022

- These results are the first reported demonstration of rapid and robust treatment changes in key disease markers associated with the severity of disease  

- Initial pharmacodynamic results for two participants show unprecedented decreases in N-acetylaspartate (NAA) in the brain and urine, suggesting the therapy is producing functional ASPA enzyme 

Read more at globenewswire.com

BRIDGEBIO PHARMA INC

NASDAQ:BBIO (5/29/2025, 8:00:01 PM)

After market: 31.88 -1.49 (-4.47%)

33.37

+1.11 (+3.44%)



Find more stocks in the Stock Screener

Follow ChartMill for more